(36) showed that first-line therapy with concurrent TKI and TRT for patients with advanced NSCLC harboring EGFR mutated provides long-term control of the primary lung lesion, with a 1-year PFS rate of 57.1% and a median PFS of 13 months that are numerically better than those of erlotinib monotherapy (43%, 11 months). Here, EGFR is linked to non-small cell lung carcinoma.